Explore the positions available across Oxford Science Enterprises

Oxford Science Enterprises (OSE) is an independent investment company founded in 2015, partnering with the University of Oxford to create transformational businesses. With a focus on deep tech, life sciences, and health tech, OSE has significantly increased investment in university spinouts, raising over £850m and investing £775m across its portfolio. The company aims to tackle global challenges by developing foundational technologies and translating novel research into new medicines, while also backing pioneers in health technology. OSE's unique partnership with Oxford University positions it as a leader in the science-business ecosystem, with a track record of successful exits and a commitment to innovation.

Aistetic is a cutting-edge AI platform that specializes in sizing and listing for fashion businesses, enabling them to enhance conversion rates by 15x and improve listing speed by 10x. The company focuses on reducing waste and improving sustainability in the fashion industry by providing accurate and automated listings and sizing solutions. Their technology is designed to integrate seamlessly with e-commerce platforms, making it accessible for businesses of all sizes. With a strong emphasis on responsible consumption and production, Aistetic positions itself as a leader in the sustainable fashion tech space, catering to both ready-to-wear and preloved markets.

Albus Health is a med-tech startup that has developed an intelligent, contactless nocturnal monitoring platform for clinical trials. Their solution enables long-term continuous monitoring of respiratory symptoms at home, providing real-time data and analytics to improve patient care. The platform has been validated against clinical gold standards and is being used in leading academic and pharmaceutical studies, showcasing its effectiveness and scalability. With a strong team of experts and backing from prestigious awards, Albus Health is positioned to disrupt the healthcare market by addressing unmet needs in respiratory monitoring.

Alethiomics is a pre-clinical biotech company focused on advancing its multi-omics target discovery pipeline specifically for blood cancer. By leveraging single-cell multi-omic technology, the company aims to uncover new biological insights that can lead to the development of life-changing treatments for patients. Their innovative approach differentiates them in the biotech space, targeting a critical area of unmet medical need. The company has gained recognition in the scientific community, as evidenced by their participation in significant events like the ASH plenary, indicating a strong market position and traction in the field of blood cancer research.

OxMet Technologies develops, licenses, and manufactures proprietary alloys, alloy powders and alloy components for the aerospace, automotive, industrial and biomedical markets.

Amber Therapeutics is pioneering the first adaptive neuromodulation therapy for women suffering from mixed urinary incontinence. Their flagship product, the Picostim TM System, is a fully implantable device that targets the pudendal nerve, providing personalized treatment by dynamically adapting to the patient's physiological responses. With a significant market need—40 million women in the US affected by urinary incontinence and only 16 million receiving therapy—Amber's innovative approach addresses both urge and stress incontinence, setting it apart from existing therapies. The company has demonstrated promising results in its AURA-2 study, showcasing safety and efficacy, and aims to transform the quality of life for millions of women globally.

Archangel Lightworks is a pioneering company focused on developing deployable laser communication systems aimed at enhancing space-enabled networks. Their innovative lasercom technology addresses critical connectivity issues faced by space and terrestrial networks, which are often hindered by traditional radio communication's limitations. By providing secure, high-bandwidth, and cost-effective solutions, Archangel Lightworks is positioned to lead in the growing market for space data applications, including climate change monitoring and logistics. Their flagship product, the TERRA-M, is designed for immediate deployment by cloud providers, network operators, and governments, showcasing their commitment to maximizing global connectivity and data utility.

BehaVR creates digital therapeutics for behavioral health using Virtual Reality. It focuses on the intersection of behavioral health and chronic disease, building skills of stress resilience, emotional regulation, and self-efficacy, helping people better cope with their conditions, be more adherent to care plans, and improve their overall health.

Bibli U is a next-generation campus bookstore and learning materials provider that empowers universities and colleges to automate learning content workflows and improve student outcomes. Their Learning Enablement platform offers digital textbooks, monographs, and courseware at a reduced cost, ensuring affordable access for all students while enhancing engagement through data-driven insights and automation. With partnerships with over 2,000 publishers and a market-leading student NPS of 70, Bibli U is positioned as a leader in digital content delivery, serving over 140 universities and colleges worldwide.

Brill Power is a clean-tech platform that develops a Battery Intelligence Platform, which enhances the performance, longevity, cost-effectiveness, and sustainability of batteries for electric vehicles and stationary energy storage. Founded in 2016 and based in Oxford, the company has made significant strides in the battery management sector, launching its first product in 2021 and expanding into new markets. With a strong focus on innovation, Brill Power has achieved impressive metrics, including up to 60% longer battery life and 30% lower lifetime costs, positioning itself as a leader in the transition to zero emissions energy.

Caristo Diagnostics is a leader in cardiac and vascular disease diagnostics, specializing in AI-assisted platforms for predicting and diagnosing heart attacks, strokes, and diabetes. Founded in 2018 from the University of Oxford, their flagship product, CaRi-Heart, utilizes advanced AI algorithms on cardiac CT scans to visualize coronary inflammation, a key risk factor for coronary artery disease. The technology is CE Mark certified and has received significant validation in leading medical journals. With over £23 million in venture capital, Caristo aims to transform cardiac care through improved risk prediction and prevention strategies.